How did FDC perform for the full fiscal year?

Full-year revenue grew by 3% to ₹2,171 crore, while net profit rose 5.5% to ₹281 crore. These figures reflect a year where domestic formulations remained flat.

What drove the sharp improvement in Q4 profitability?

Profitability rose because EBITDA margins reached 18.2% compared to 11% in the same quarter last year. A 283% revenue spike in the US formulations business also contributed to the bottom-line growth.

Did the company receive any new regulatory approvals?

Yes, FDC received US FDA approval for fluconazole tablets during the fourth quarter.

Is this quarterly result a change in the company's annual trajectory?

No. The full-year growth remains at 3%, indicating that the strong Q4 does not alter the annual trend.

Earnings · Pharmaceuticals · Mid cap

FDC ends FY26 with a strong Q4 as US exports surge

A 283% jump in US formulations helped FDC double its quarterly profit to ₹103 crore, though full-year growth remains muted at 3%.

— 2 earlier stories on FDC Ltd. →

FDC 27 May 2026 · 3:42 PM IST Verify on BSE · NSE

Mkt cap₹6,994 cr

P/E32.27×

ROE11.70%

Debt / eq.0.00

Div yld1.17%

₹103 cr Consolidated net profit for Q4 FY26, more than double the prior year.

What's new

Q4 revenue rose 18.9% to ₹585 crore, with net profit hitting ₹103 crore.
US formulations revenue climbed 283% to ₹39 crore during the quarter.
EBITDA margins expanded to 18.2% from 11% in the same period last year.

Why this matters

The quarterly surge provides a lift after a sluggish year for FDC's domestic business. The annual growth of 3% shows that the core domestic portfolio remains a drag on performance.

What we're watching

Whether the US momentum in fluconazole tablets can offset flat domestic sales.
Sustainability of the 18.2% EBITDA margin in the coming fiscal year.
Signs of recovery in top domestic brands that weighed on FY26 performance.

The full read

FDC closed FY26 with a strong fourth quarter, reporting a 18.9% year-on-year revenue increase to ₹585 crore. Net profit more than doubled to ₹103 crore, aided by a 283% surge in US formulations revenue to ₹39 crore and an expansion in EBITDA margins to 18.2% from 11% a year ago. The full-year picture is more subdued. Revenue for the year rose just 3% to ₹2,171 crore, while net profit grew 5.5% to ₹281 crore. The disparity between the quarterly spike and the annual stagnation points to the ongoing struggle in FDC's domestic formulations business, where top brands have remained sluggish. The US FDA approval for fluconazole tablets and the margin improvement are positive signs, but the company faces the challenge of translating this quarterly recovery into consistent annual growth.

Questions answered

How did FDC perform for the full fiscal year?: Full-year revenue grew by 3% to ₹2,171 crore, while net profit rose 5.5% to ₹281 crore. These figures reflect a year where domestic formulations remained flat.
What drove the sharp improvement in Q4 profitability?: Profitability rose because EBITDA margins reached 18.2% compared to 11% in the same quarter last year. A 283% revenue spike in the US formulations business also contributed to the bottom-line growth.
Did the company receive any new regulatory approvals?: Yes, FDC received US FDA approval for fluconazole tablets during the fourth quarter.
Is this quarterly result a change in the company's annual trajectory?: No. The full-year growth remains at 3%, indicating that the strong Q4 does not alter the annual trend.

Mentioned: FDC Ltd · US FDA

Primary source BSE · NSE

An independent reading of the company's own disclosure — the primary filing above is the final word.

Story so far

All notes on FDC →

27 May 2026 · 3:42 PM IST FDC ends FY26 with a strong Q4 as US exports surge
today FDC Ltd. closes FY26 with modest growth and a strong Q4 finish
today FDC ends FY26 with 2.7% revenue growth as Q4 profit surges